改善精神分裂症患者的功能：阿立哌唑一月一次（REACT 研究）的真实世界疗效。
Improvement of functioning in patients with schizophrenia: real-world effectiveness of aripiprazole once-monthly (REACT study).
机构信息
University of Calgary, 2500 University Drive NW, Calgary, AB, T2N 1N4, Canada.
Lundbeck Canada Inc, 2600 Alfred-Nobel Boulevard, Saint-Laurent, QC, H4S 0A9, Canada.
出版信息
BMC Psychiatry. 2023 May 31;23(1):383. doi: 10.1186/s12888-023-04893-8.
BACKGROUND
Functional impairment affects many patients with schizophrenia. Treatment with the long-acting injectable antipsychotic aripiprazole once-monthly (AOM) may help improve functioning.
OBJECTIVES
To explore changes in functioning in patients with schizophrenia who received AOM treatment in observational studies.
METHODS
Here we report functional outcomes in the form of Global Assessment of Functioning (GAF) scores in a pooled analysis of data from two observational studies from Canada (NCT02131415) and Germany (vfa non-interventional studies registry 15960N). Data from 396 patients were analyzed.
RESULTS
At baseline, the mean GAF score was 47.7 (SD 13.4). During 6 months of treatment with AOM, the mean GAF score increased to 59.4 (SD 15.8). Subgroups stratified by patient age (≤35 years/>35 years), sex, disease duration (≤5 years/>5 years) and disease severity at baseline had all significantly improved their GAF at month 6. 51.5% of the patients showed a GAF score increase of at least 10 points, which was regarded as clinically meaningful, and were considered responders.
CONCLUSIONS
These data show that treatment with AOM may help improve patient functioning in a routine treatment setting.
TRIAL REGISTRATION
NCT02131415 (May 6, 2014), vfa non-interventional studies registry 15960N.
背景
功能障碍影响许多精神分裂症患者。长效注射用抗精神病药阿立哌唑每月一次（AOM）治疗可能有助于改善功能。
目的
在观察性研究中探讨接受 AOM 治疗的精神分裂症患者功能的变化。
方法
我们在此报告来自加拿大（NCT02131415）和德国（vfa 非干预性研究登记 15960N）两项观察性研究数据的汇总分析中以总体功能评估（GAF）评分形式呈现的功能结果。共分析了 396 例患者的数据。
结果
基线时，平均 GAF 评分为 47.7（SD 13.4）。在接受 AOM 治疗的 6 个月期间，平均 GAF 评分增加到 59.4（SD 15.8）。按患者年龄（≤35 岁/>35 岁）、性别、疾病持续时间（≤5 年/>5 年）和基线疾病严重程度分层的亚组在第 6 个月时均显著改善了 GAF。51.5%的患者 GAF 评分至少增加了 10 分，这被认为具有临床意义，被认为是应答者。
结论
这些数据表明，在常规治疗环境中，AOM 治疗可能有助于改善患者的功能。
试验注册
NCT02131415（2014 年 5 月 6 日），vfa 非干预性研究登记 15960N。
Zotero 插件